Synergy between vascular targeting agents and antibody-directed therapy

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1524-1531

  Pedley, R Barbara ^a   El Emir, Ethaar ^a   Flynn, Aiden A ^a   Boxer, Geoffrey M ^a   Dearling, Jason ^a   Raleigh, James A ^b   Hill, Sally A ^c   Stuart, Sam ^a   Motha, Reeya ^a   Begent, Richard H J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Combined therapy; Digital microscopy; Radioimmunotherapy; Vascular targeting agents

Indexed keywords

RADIOLUMINOGRAPHY;

ANTIBODIES; BLOOD VESSELS; LIVING SYSTEMS STUDIES; PHYSIOLOGY; RADIOGRAPHY; TUMORS;

RADIOTHERAPY;

CARCINOEMBRYONIC ANTIBODY; COMBRETASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD VESSEL; COLORECTAL TUMOR; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HISTOCHEMISTRY; HYPOXIA; MORPHOLOGY; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TISSUE OXYGENATION;

ANGIOGENESIS INHIBITORS; ANIMALS; COMBINED MODALITY THERAPY; IMMUNOGLOBULIN G; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIOIMMUNOTHERAPY; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036891507     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03923-8     Document Type: Conference Paper

References (36)

1. Jain R.K. The next frontier of molecular medicine Delivery of therapeutics . Nat Med. 4:1998;655-657.
2. Glennie M.J., Johnson P.W.M. Clinical trials of antibody therapy. Immunology Today. 21:2000;403-410.
3. Pedley R.B. Pharmacokinetics of monoclonal antibodies Implications for their use in cancer therapy . Clinical Immunotherapeutics. 6:1996;54-67.
4. Bagshawe K.D. Antibody-directed enzyme prodrug therapy A review . Drug Dev Res. 34:1995;220-230.
5. Napier M.P., Begent R.H.J. Radioimmunotherapy of gastrointestinal cancer. Riva T. Cancer radioimmunotherapy. 1998;333-388 Harwood Academia, Boston.
6. Blakey D.C., Burke P.J., Davies D.H., et al. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts. Cancer Res. 56:1996;3287-3292.
7. Pedley R.B., Begent R.H.J., Boden J.A., et al. Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft. Int J Cancer. 57:1984;830-835.
8. Napier M.P., Sharma S.K., Springer C.J., et al. Antibody-directed enzyme prodrug therapy Efficacy and mechanism of action in colorectal carcinoma . Clin Cancer Res. 6:2000;765-772.
9. Pedley R.B., Boden J.A., Boden R., et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow modifying agents. Cancer Res. 56:1996;3293-3300.
10. Pedley R.B., Hill S.A., Boxer G.M., et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A4-phosphate. Cancer Res. 61:2001;4716-4722.
11. Flynn A.A., Green A.J., Boxer G.M., et al. A novel technique, using radioluminography, for the measurement of uniformity of radiolabeled antibody distribution on a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys. 43:1999;183-189.
12. Flynn A.A., Green A.J., Pedley R.B., et al. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer. 15:2002;1249-1257.
13. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol. 23:1984;217-225.
14. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A. 90:1993;8996-9000.
15. Tozer G.M., Kanthou C., Parkins C.S., et al. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 83:2002;21-38.
16. Lash C.J., Li A.E., Rutland M., et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 78:1998;439-445.
17. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
18. Grosios K., Howell S.E., McGown A.T., et al. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer. 81:1999;1318-1327.
19. Wilson W.R., Li A.E., Cowan D.S., et al. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethyl xanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys. 42:1998;905-908.
20. Zwi L.J., Baguley B.C., Gavin J.B., et al. The morphological effects of anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on colon 38 mouse tumour. Pathology. 24:1994;161-169.
21. Pedley R.B., Sharma S.K., Boxer G.M., et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59:1999;3998-4003.
22. Tozer G.M., Prise V.E., Wilson J., et al. A-4 phosphate as a tumor vascular-targeting agent Early effects in tumors and normal tissues . Cancer Res. 59:1999;1626-1634.
23. Galbraith S.M., Taylor N.J., Rustin G.J.S., et al. Changes in human tumour perfusion after DMXAA treatment, monitored by Gd-DTPA enhanced MRI. (Abstr) Br J Cancer. 78:1998;11.
24. Griggs J., Metcalfe J.C., Hesketh R. Targeting tumour vasculature The development of combretastatin A4 . Lancet Oncol. 2:2001;82-87.
25. 2 antibodies . Br J Cancer. 70:1994;521-525.
26. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxic marker. Cancer Res. 58:1998;3765-3768.
27. Vecchi A., Garlanda C., Lampugnani M.G., et al. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol. 63:1994;247-254.
28. Looney W.B., Mayo A.A., Allen P.M., et al. A mathematical evaluation of tumour growth curves in rapid, intermediate and slow growing rat hepatoma. Br J Cancer. 27:1973;341-344.
29. Lee E., Desu M. A computer program for comparing K samples with right censored data. Computer Prog Biomed. 2:1972;315-321.
30. Flynn A.A., Pedley R.B., Green A.J., et al. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of tumor sections. Cancer Biother Radiopharm. 16:2001;391-400.
31. Flynn A.A., Boxer G.M., Begent R.H.J., et al. Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother. 50:2001;77-81.
32. Chaplin D.J., Petit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy Evaluation of combretastatin A4 phosphate . Anticancer Res. 19:1999;189-196.
33. Rijken P.F.J.W., Bernsen H.J.J.A., Van der Kogel A.J. Application of an image analysis system to the quantitation of tumor perfusion and vascularity in human glioma xenografts. Microvasc Res. 50:1995;141-153.
34. Bussink J., Kaanders J.H.A.M., Rijken P., et al. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts Effects of carbogen and nicotinamide . Radiother Oncol. 50:1999;173-184.
35. Ljungkvist A.S.E., Bussink J., Rijken P.F.J.W., et al. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys. 48:2000;1529-1538.
36. Busch T.M., Hahn S.M., Evans S.M., et al. Depletion of tumor oxygenation during photodynamic therapy Detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide] . Cancer Res. 60:2000;2636-2642.